Literature DB >> 30558722

The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment.

Kelly J Lafaro1, Laleh G Melstrom2.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is increasing in incidence and is projected to become the second leading cause of cancer death in the United States. Despite significant advances in understanding the disease, there has been minimal increase in PDAC patient survival. PDAC tumors are unique in the fact that there is significant desmoplasia. This generates a large stromal compartment composed of immune cells, inflammatory cells, growth factors, extracellular matrix, and fibroblasts, comprising the tumor microenvironment (TME), which may represent anywhere from 15% to 85% of the tumor. It has become evident that the TME, including both the stroma and extracellular component, plays an important role in tumor progression and chemoresistance of PDAC. This review will discuss the multiple components of the TME, their specific impact on tumorigenesis, and the multiple therapeutic targets.
Copyright © 2019 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 30558722      PMCID: PMC6315325          DOI: 10.1016/j.ajpath.2018.09.009

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  113 in total

1.  Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer.

Authors:  Takuma Aikawa; Jason Gunn; Suzanne M Spong; Stephen J Klaus; Murray Korc
Journal:  Mol Cancer Ther       Date:  2006-05       Impact factor: 6.261

2.  A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.

Authors:  Andrew H Ko; Noelle LoConte; Margaret A Tempero; Evan J Walker; R Kate Kelley; Stephanie Lewis; Wei-Chou Chang; Emily Kantoff; Michael W Vannier; Daniel V Catenacci; Alan P Venook; Hedy L Kindler
Journal:  Pancreas       Date:  2016-03       Impact factor: 3.327

3.  CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer.

Authors:  Albrecht Neesse; Kristopher K Frese; Tashinga E Bapiro; Tomoaki Nakagawa; Mark D Sternlicht; Todd W Seeley; Christian Pilarsky; Duncan I Jodrell; Suzanne M Spong; David A Tuveson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-08       Impact factor: 11.205

4.  CXCL12/CXCR4 protein signaling axis induces sonic hedgehog expression in pancreatic cancer cells via extracellular regulated kinase- and Akt kinase-mediated activation of nuclear factor κB: implications for bidirectional tumor-stromal interactions.

Authors:  Ajay P Singh; Sumit Arora; Arun Bhardwaj; Sanjeev K Srivastava; Madhavi P Kadakia; Bin Wang; William E Grizzle; Laurie B Owen; Seema Singh
Journal:  J Biol Chem       Date:  2012-09-20       Impact factor: 5.157

Review 5.  Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells.

Authors:  Bryan P Toole; Mark G Slomiany
Journal:  Semin Cancer Biol       Date:  2008-03-26       Impact factor: 15.707

6.  Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells.

Authors:  M V Apte; S Park; P A Phillips; N Santucci; D Goldstein; R K Kumar; G A Ramm; M Buchler; H Friess; J A McCarroll; G Keogh; N Merrett; R Pirola; J S Wilson
Journal:  Pancreas       Date:  2004-10       Impact factor: 3.327

7.  A paracrine requirement for hedgehog signalling in cancer.

Authors:  Robert L Yauch; Stephen E Gould; Suzie J Scales; Tracy Tang; Hua Tian; Christina P Ahn; Derek Marshall; Ling Fu; Thomas Januario; Dara Kallop; Michelle Nannini-Pepe; Karen Kotkow; James C Marsters; Lee L Rubin; Frederic J de Sauvage
Journal:  Nature       Date:  2008-08-27       Impact factor: 49.962

8.  Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression.

Authors:  Fieke E M Froeling; Christine Feig; Claude Chelala; Richard Dobson; Charles E Mein; David A Tuveson; Hans Clevers; Ian R Hart; Hemant M Kocher
Journal:  Gastroenterology       Date:  2011-06-24       Impact factor: 22.682

9.  Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer.

Authors:  Srinivasa P Pothula; Zhihong Xu; David Goldstein; Andrew V Biankin; Romano C Pirola; Jeremy S Wilson; Minoti V Apte
Journal:  Br J Cancer       Date:  2016-01-14       Impact factor: 7.640

Review 10.  Genetics and biology of pancreatic ductal adenocarcinoma.

Authors:  Haoqiang Ying; Prasenjit Dey; Wantong Yao; Alec C Kimmelman; Giulio F Draetta; Anirban Maitra; Ronald A DePinho
Journal:  Genes Dev       Date:  2016-02-15       Impact factor: 11.361

View more
  25 in total

1.  Circ_0006790 carried by bone marrow mesenchymal stem cell-derived exosomes regulates S100A11 DNA methylation through binding to CBX7 in pancreatic ductal adenocarcinoma.

Authors:  Ge Gao; Liqiang Wang; Changfeng Li
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

Review 2.  The Desmoplastic Stroma of Pancreatic Cancer: Multilayered Levels of Heterogeneity, Clinical Significance, and Therapeutic Opportunities.

Authors:  Yohei Masugi
Journal:  Cancers (Basel)       Date:  2022-07-05       Impact factor: 6.575

3.  Conditioned media of pancreatic cancer cells and pancreatic stellate cells induce myeloid-derived suppressor cells differentiation and lymphocytes suppression.

Authors:  Yuen Ping Chong; Evelyn Priya Peter; Feon Jia Ming Lee; Chu Mun Chan; Shereen Chai; Lorni Poh Chou Ling; Eng Lai Tan; Sook Han Ng; Atsushi Masamune; Siti Aisyah Abd Ghafar; Norsharina Ismail; Ket Li Ho
Journal:  Sci Rep       Date:  2022-07-19       Impact factor: 4.996

Review 4.  Advanced iron oxide nanotheranostics for multimodal and precision treatment of pancreatic ductal adenocarcinoma.

Authors:  Lei Zhu; Hui Mao; Lily Yang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2022-04-09

5.  Selective Labeling and Identification of the Tumor Cell Proteome of Pancreatic Cancer In Vivo.

Authors:  Nancy G Azizian; Delaney K Sullivan; Litong Nie; Sammy Pardo; Dana Molleur; Junjie Chen; Susan T Weintraub; Yulin Li
Journal:  J Proteome Res       Date:  2020-12-08       Impact factor: 4.466

6.  Circulating Inflammation Markers and Pancreatic Cancer Risk: A Prospective Case-Cohort Study in Japan.

Authors:  Enbo Ma; Taichi Shimazu; Minkyo Song; Hadrien Charvat; Norie Sawada; Taiki Yamaji; Manami Inoue; M Constanza Camargo; Troy J Kemp; Ruth M Pfeiffer; Ligia A Pinto; Charles S Rabkin; Shoichiro Tsugane
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-10-25       Impact factor: 4.090

7.  Inhibition of de novo pyrimidine synthesis augments Gemcitabine induced growth inhibition in an immunocompetent model of pancreatic cancer.

Authors:  Thuy Phan; Vu H Nguyen; Ralf Buettner; Corey Morales; Lifeng Yang; Paul Wong; Weiman Tsai; Marcela d'Alincourt Salazar; Ziv Gil; Don J Diamond; Joshua D Rabinowitz; Steven Rosen; Laleh G Melstrom
Journal:  Int J Biol Sci       Date:  2021-06-01       Impact factor: 6.580

Review 8.  [The microarchitecture of pancreatic cancer from the point of view of the pathologist and the radiologist].

Authors:  Philipp Mayer; Matthias M Gaida
Journal:  Pathologe       Date:  2021-05-06       Impact factor: 1.011

Review 9.  Fibrosis and cancer: A strained relationship.

Authors:  Bram Piersma; Mary-Kate Hayward; Valerie M Weaver
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-03-05       Impact factor: 11.414

10.  Tumor-insular Complex in Neoadjuvant Treated Pancreatic Ductal Adenocarcinoma Is Associated With Higher Residual Tumor.

Authors:  Iván A González; Liang-I Kang; Gregory A Williams; Jingxia Liu; David G DeNardo; William G Hawkins; Deyali Chatterjee
Journal:  Am J Surg Pathol       Date:  2020-06       Impact factor: 6.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.